Advances in our knowledge of cell signaling and biology have led to the development of products that may guide the healing/regenerative process. Therapies are emerging that involve growth factors, blood-derived products, marrow-derived products, and stem cells. Animal studies suggest that genetic modification of stem cells will be necessary; studies of cartilage and meniscus regeneration indicate that immature cells are effective and that scaffolds are not always necessary. Current preclinical animal and clinical human data and regulatory requirements are important to understand in light of public interest in these products.
Dr. Anz or an immediate family member serves as a paid consultant to Ceterix Orthopaedics, Arthrex, and MicroAire and has received institutional support from Celling Biosciences and Ceterix Orthopaedics. Dr. Nilssen or an immediate family member is a member of a speakers’ bureau or has made paid presentations on behalf of Arthrex, ETEX, and Medartis; is an employee of ASE Medical; serves as a paid consultant to ETEX and Medartis; and has stock or stock options held in Tenex Health, CorMatrix, ETEX, and Fuse Medical. Dr. Andrews or an immediate family member has received royalties from Biomet Sports Medicine; serves as a paid consultant to Biomet Sports Medicine, Bauerfeind, Theralase Technologies, and MiMedx; is an employee of Physiotherapy Associates; has stock or stock options held in Patient Connection and Connective Orthopaedics; and serves as a board member, owner, officer, or committee member of FastHealth Corporation and Physiotherapy Associates. Neither Dr. Hackel nor any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article.
From the Andrews Research & Education Institute, Gulf Breeze, FL.